KeyMed Biosciences Inc
HKEX:2162
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
CN |
|
Hindustan Petroleum Corp Ltd
NSE:HINDPETRO
|
IN |
|
T
|
Tanco Holdings Bhd
KLSE:TANCO
|
MY |
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
IE |
Balance Sheet
Balance Sheet Decomposition
KeyMed Biosciences Inc
KeyMed Biosciences Inc
Balance Sheet
KeyMed Biosciences Inc
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
433
|
199
|
1 521
|
604
|
851
|
418
|
|
| Cash |
433
|
199
|
981
|
588
|
813
|
276
|
|
| Cash Equivalents |
0
|
0
|
540
|
16
|
38
|
142
|
|
| Short-Term Investments |
66
|
155
|
2 004
|
2 571
|
1 868
|
1 737
|
|
| Total Receivables |
1
|
1
|
14
|
7
|
37
|
69
|
|
| Accounts Receivables |
0
|
0
|
4
|
0
|
27
|
63
|
|
| Other Receivables |
0
|
0
|
10
|
7
|
10
|
7
|
|
| Inventory |
3
|
7
|
16
|
44
|
56
|
111
|
|
| Other Current Assets |
15
|
19
|
27
|
83
|
127
|
130
|
|
| Total Current Assets |
518
|
381
|
3 582
|
3 310
|
2 940
|
2 466
|
|
| PP&E Net |
129
|
126
|
306
|
596
|
911
|
1 075
|
|
| PP&E Gross |
129
|
126
|
306
|
596
|
911
|
1 075
|
|
| Accumulated Depreciation |
10
|
24
|
35
|
57
|
109
|
184
|
|
| Intangible Assets |
0
|
0
|
1
|
1
|
1
|
10
|
|
| Note Receivable |
9
|
20
|
22
|
1
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
20
|
21
|
22
|
210
|
|
| Other Long-Term Assets |
2
|
2
|
2
|
3
|
10
|
5
|
|
| Total Assets |
659
N/A
|
530
-20%
|
3 934
+642%
|
3 932
0%
|
3 883
-1%
|
3 767
-3%
|
|
| Liabilities | |||||||
| Accounts Payable |
3
|
3
|
3
|
15
|
29
|
26
|
|
| Accrued Liabilities |
7
|
16
|
51
|
92
|
112
|
123
|
|
| Short-Term Debt |
11
|
11
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
4
|
4
|
12
|
72
|
65
|
485
|
|
| Other Current Liabilities |
46
|
46
|
47
|
201
|
107
|
114
|
|
| Total Current Liabilities |
72
|
80
|
112
|
380
|
314
|
748
|
|
| Long-Term Debt |
128
|
1 406
|
27
|
50
|
353
|
269
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
6
|
1
|
1
|
1
|
|
| Other Liabilities |
735
|
138
|
150
|
164
|
228
|
275
|
|
| Total Liabilities |
935
N/A
|
1 624
+74%
|
283
-83%
|
592
+109%
|
897
+51%
|
1 292
+44%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
276
|
1 095
|
4 865
|
5 145
|
5 498
|
6 022
|
|
| Additional Paid In Capital |
0
|
0
|
8 516
|
8 485
|
8 484
|
8 496
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
117
|
145
|
0
|
0
|
|
| Total Equity |
276
N/A
|
1 095
-297%
|
3 651
N/A
|
3 340
-9%
|
2 986
-11%
|
2 475
-17%
|
|
| Total Liabilities & Equity |
659
N/A
|
530
-20%
|
3 934
+642%
|
3 932
0%
|
3 883
-1%
|
3 767
-3%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
271
|
271
|
280
|
277
|
279
|
279
|
|